Trivant Custom Portfolio Group, LLC Travere Therapeutics, Inc. Transaction History
Trivant Custom Portfolio Group, LLC
- $174 Billion
- Q1 2025
A detailed history of Trivant Custom Portfolio Group, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Trivant Custom Portfolio Group, LLC holds 100 shares of TVTX stock, worth $2,081. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100Holding current value
$2,081% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding TVTX
# of Institutions
219Shares Held
94.3MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$159 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$153 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$140 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$104 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$88.6 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.34B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...